Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Single-Dose Flu Drug Shows Promise in Trials

September 8, 2014 10:54 am | News | Comments

BioCryst Pharmaceuticals Inc. announced trial results related to Rapivab (peramivir injection), a neuraminidase inhibitor (NAI) for the treatment of influenza, at the ICAAC. Read more...                   

TOPICS:

EU Approves Roche's RoACTEMRA for RA

September 8, 2014 10:43 am | News | Comments

Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA. Read more...                       

TOPICS:

NIH Finds More Forgotten Germs in Labs

September 8, 2014 10:35 am | by Lauran Neergaard, AP Medical Writer | News | Comments

The National Institutes of Health said it has uncovered a nearly century-old container of ricin and a handful of other forgotten samples of dangerous pathogens as it combs its laboratories for improperly stored hazardous materials. Read more...  

TOPICS:
Advertisement

Ebola Surging Where it Had Been Beaten Back

September 8, 2014 10:30 am | by Boubacar Diallo and Sarah DiLorenzo | News | Comments

Doctors Without Borders shuttered one of its Ebola treatment centers in Guinea in May, thinking the virus was being contained there. The Macenta region, right on the Liberian border, had been one of the first places where the outbreak surfaced, but they hadn't seen a new case for weeks. Now, months later, Macenta is once again a hotspot. Read more...

TOPICS:

Ascendia Advances Nano-Emulsion Technology Platform with ASD-002 Program

September 5, 2014 3:06 pm | News | Comments

Ascendia Pharmaceuticals announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel- the world’s top-selling blood thinner medicine. Read more...       

TOPICS:

Soligenix Acquires Phase-3-Ready Oncology Program

September 5, 2014 2:58 pm | News | Comments

Soligenix Inc. announced the acquisition of a novel orphan drug candidate, known as SGX301, which is poised to enter pivotal Phase 3 clinical testing for the treatment of cutaneous T-cell lymphoma and is highly synergistic with the company’s existing development pipeline. Read more...

TOPICS:

FDA Lifts Partial Hold on OncoMed's Cancer Drug

September 5, 2014 2:52 pm | News | Comments

OncoMed Pharmaceuticals announced that the FDA removed the partial clinical hold on the company's ipafricept (FZD8-Fc, OMP-54F28) Phase 1 clinical trials. Read more...                        

TOPICS:

U.S. in Danger of Losing Biotech Edge, Experts Say

September 5, 2014 2:48 pm | News | Comments

The United States is in danger of losing its biomedical edge to countries that are aggressively funding research into personalized medicine, according to experts in the field. Read more...

TOPICS:
Advertisement

WHO Backs Use of Survivors' Blood as Ebola Treatment

September 5, 2014 2:42 pm | News | Comments

The World Health Organization recommends that doctors should use blood from survivors to treat patients in an effort to combat the biggest-ever outbreak of Ebola. Read more...                      

TOPICS:

Newly Approved Kidney Drug Gets Unexpected Safety Warning

September 5, 2014 2:34 pm | News | Comments

Keryx Biopharmaceuticals received approval Friday for a pill to treat complications of kidney disease in dialysis patients, but the company's stock fell as investors reacted to an unexpected safety warning in the drug's prescribing label. Read more...

TOPICS:

NeuroDerm Starts Phase 2a Study of Parkinson’s Drug

September 5, 2014 11:11 am | News | Comments

NeuroDerm Ltd. announced that the first patients with severe Parkinson’s disease have been enrolled and dosed in a Phase 2a trial of ND0612H, a high-dose form of NeuroDerm’s proprietary liquid levodopa/carbidopa (LD/CD) drug formulation. Read more...

TOPICS:

Antisense Acromegaly Drug Shows Efficacy in Phase 2

September 5, 2014 11:04 am | News | Comments

Antisense Therapeutics Ltd. reported the primary efficacy results from its Phase 2 clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. Read more...               

TOPICS:

Flu Vaccine Protects Mothers, Babies

September 5, 2014 10:53 am | News | Comments

A new study shows that the influenza vaccination of pregnant HIV-uninfected and HIV-infected women is safe and protects the women against confirmed influenza illness. Read more...                     

TOPICS:

Actavis Antibiotic NDA Accepted, Deemed QIDP

September 5, 2014 10:27 am | News | Comments

Actavis plc confirmed that the FDA has accepted for filing Actavis' application for ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections. Read more...

TOPICS:

U.S. to Give $75M to Expand Ebola Care Centers

September 5, 2014 10:19 am | by Jonathan Paye-Layleh and Sarah DiLorenzo | News | Comments

The American aid agency announced Thursday it would donate $75 million to fund 1,000 more beds in Ebola treatment centers in Liberia and buy 130,000 more protective suits for health care workers. Read more...            

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading